Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Lars Friedrich is a scientist at XL-protein, a company dedicated to the development of superior biopharmaceuticals with extended plasma half-life. Trained as a protein engineering specialist with biology background, he is substantially involved in the company’s recent research projects on antibody-drug conjugates. Beside his activities as project manager responsible for several feasibility studies on biobetters, his work focuses on the development of PAS biopolymers for chemical conjugation.
Before joining XL-protein in 2013, he accomplished his Ph.D. studies at the Technical University of Munich (Germany) under supervision of Prof. Dr. Arne Skerra. His project involved the development of directed evolution strategies for the generation of novel binding proteins (Anticalins) and their functionalization for tumour diagnosis and therapy.
Lars Friedrich studied Biology at the Technical University of Dresden (Germany) and the Federal University of Rio Grande do Sul (Brazil), majoring in Molecular Genetics and Biochemistry. He received his diploma degree in 2007. His ongoing interest in protein science emerged during his diploma study on a metal-dependent self-cleaving protein domain that is found in several symbiotic and pathogenic bacteria.